Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Safety, Tolerability and Proof of Concept Study of ST101 for Essential Tremor
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2012
Price :
$35
*
At a glance
- Drugs ST 101 (Primary)
- Indications Essential tremor
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 05 Jan 2012 Actual patient number (25) added as reported by ClinicalTrials.gov.
- 05 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2011 Planned end date changed from 1 Oct 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.